Tobacco Use and the Cancer Patient

Jun 28, 2016 by in ONCOLOGY Comments Off on Tobacco Use and the Cancer Patient

Tobacco Use and the Cancer Patient Graham W. Warren Benjamin A. Toll Irene M. Tamí-Maury Ellen R. Gritz INTRODUCTION Tobacco is commonly described as the largest preventable cause of cancer….

read more

Assessment of Clinical Response

Jun 28, 2016 by in ONCOLOGY Comments Off on Assessment of Clinical Response

Assessment of Clinical Response Antonio Tito Fojo Susan E. Bates INTRODUCTION Approaches to response assessments have become increasingly important over the past decade as the drug development pipeline has steadily…

read more

Monoclonal Antibodies

Jun 28, 2016 by in ONCOLOGY Comments Off on Monoclonal Antibodies

Monoclonal Antibodies Hossein Borghaei Matthew K. Robinson Gregory P. Adams Louis M. Weiner INTRODUCTION Antibody-based therapeutics are important components of the cancer therapeutic armamentarium. Early antibody therapy studies attempted to…

read more

Antiangiogenesis Agents

Jun 28, 2016 by in ONCOLOGY Comments Off on Antiangiogenesis Agents

Antiangiogenesis Agents Cindy H. Chau William Douglas Figg Sr. INTRODUCTION Blood vessels are indispensable for tumor growth and metastasis, and the formation of a new network of blood vessels from…

read more

Hormonal Agents

Jun 28, 2016 by in ONCOLOGY Comments Off on Hormonal Agents

Hormonal Agents Matthew P. Goetz Charles Erlichman Charles L. Loprinzi Manish Kohli INTRODUCTION Hormonal agents are commonly used as a treatment of hormonally responsive cancers, such as breast, prostate, or…

read more

Miscellaneous Chemotherapeutic Agents

Jun 28, 2016 by in ONCOLOGY Comments Off on Miscellaneous Chemotherapeutic Agents

Miscellaneous Chemotherapeutic Agents M. Sitki Copur Scott Nicholas Gettinger Sarah B. Goldberg Hari A. Deshpande HOMOHARRINGTONINE AND OMACETAXINE Homoharringtonine and its congener, harringtonine, are cephalotaxine esters isolated from the evergreen…

read more

Poly (ADP-ribose) Polymerase Inhibitors

Jun 28, 2016 by in ONCOLOGY Comments Off on Poly (ADP-ribose) Polymerase Inhibitors

Poly (ADP-ribose) Polymerase Inhibitors Alan Ashworth INTRODUCTION Cancer cells may harbor defects in DNA repair pathways leading to genomic instability. This can foster tumorigenesis but also provides a weakness that…

read more

Proteasome Inhibitors

Jun 28, 2016 by in ONCOLOGY Comments Off on Proteasome Inhibitors

Proteasome Inhibitors Christopher J. Kirk Brian B. Tuch Shirin Arastu-Kapur Lawrence H. Boise BIOCHEMISTRY OF THE UBIQUITIN-PROTEASOME PATHWAY The ubiquitin proteasome system is involved in the degradation of more than…

read more

Kinase Inhibitors as Anticancer Drugs

Jun 28, 2016 by in ONCOLOGY Comments Off on Kinase Inhibitors as Anticancer Drugs

Kinase Inhibitors as Anticancer Drugs Charles L. Sawyers INTRODUCTION In 2001, the first tyrosine-kinase inhibitor imatinib was approved for clinical use in chronic myeloid leukemia. The spectacular success of this…

read more
Premium Wordpress Themes by UFO Themes